RecruitingObservationalLast updated Jul 2, 2026

Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

Prediction Study or Response to Treatment With Anti-CGRP Monoclonal Antibodies in Migraine

Overview

ClinicalTrials.gov ID: NCT06459648
Lead Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La PrincesaOTHER
Brief Summary: Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.

Status

Study Record Dates

NCT05232942Unknown status

Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption

NCT07159750Recruiting

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

NCT04503083Completed

BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies

NCT05785988Unknown status

Anti-CGRP Monoclonal Antibody Response After Switching (AMARAS)

NCT06692088Not yet recruiting

"Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment"

NCT05281770Unknown status

Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study